Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1) : Implications for GLP-1 measurements in clinical studies. / Bak, Monika Judyta; Albrechtsen, Nicolai Jacob Wewer; Pedersen, Jens; Knop, Filip Krag; Vilsbøll Lauritsen, Tina; Jørgensen, Nils B; Hartmann, Bolette; Deacon, Carolyn F.; Dragsted, Lars Ove; Holst, Jens Juul.

In: Diabetes, Obesity and Metabolism, Vol. 16, No. 11, 2014, p. 1155-1164.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bak, MJ, Albrechtsen, NJW, Pedersen, J, Knop, FK, Vilsbøll Lauritsen, T, Jørgensen, NB, Hartmann, B, Deacon, CF, Dragsted, LO & Holst, JJ 2014, 'Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies', Diabetes, Obesity and Metabolism, vol. 16, no. 11, pp. 1155-1164. https://doi.org/10.1111/dom.12352

APA

Bak, M. J., Albrechtsen, N. J. W., Pedersen, J., Knop, F. K., Vilsbøll Lauritsen, T., Jørgensen, N. B., ... Holst, J. J. (2014). Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies. Diabetes, Obesity and Metabolism, 16(11), 1155-1164. https://doi.org/10.1111/dom.12352

Vancouver

Bak MJ, Albrechtsen NJW, Pedersen J, Knop FK, Vilsbøll Lauritsen T, Jørgensen NB et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies. Diabetes, Obesity and Metabolism. 2014;16(11):1155-1164. https://doi.org/10.1111/dom.12352

Author

Bak, Monika Judyta ; Albrechtsen, Nicolai Jacob Wewer ; Pedersen, Jens ; Knop, Filip Krag ; Vilsbøll Lauritsen, Tina ; Jørgensen, Nils B ; Hartmann, Bolette ; Deacon, Carolyn F. ; Dragsted, Lars Ove ; Holst, Jens Juul. / Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1) : Implications for GLP-1 measurements in clinical studies. In: Diabetes, Obesity and Metabolism. 2014 ; Vol. 16, No. 11. pp. 1155-1164.

Bibtex

@article{cd05f89eae6f4fc68a2286f27f352022,
title = "Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies",
abstract = "AIMS: To evaluate performances of commercially available glucagon-like peptide-1 (GLP-1) assays and implications for clinical studies.MATERIALS AND METHODS: Known concentrations (5-300 pmol/l) of synthetic GLP-1 isoforms (GLP-1 1-36NH2 , 7-36NH2 , 9-36NH2 , 1-37, 7-37 and 9-37) were added to the matrix (assay buffer) supplied with ten different kits and to human plasma, and recoveries determined. Assays giving meaningful results were analysed for precision and sensitivity by repeated analysis and ability to discriminate low concentrations. Endogenous GLP-1 levels in clinical samples were assessed with 3 commercial kits.RESULTS: The USCN LIFE assay detected none of the GLP-1 isoforms. The active GLP-1 ELISAs from Millipore and DRG seemed identical and were specific for intact GLP-1 in buffer and plasma. The Meso Scale Discovery Total GLP-1 kit detected all six GLP-1 isoforms, although recovery of non-active forms was incomplete, especially in plasma. Millipore Total GLP-1 ELISA kit detected all isoforms in buffer, but mainly amidated forms in plasma. The Alpco, Phoenix and Bio-Rad kits detected only amidated GLP-1,but the Alpco kit had a limited measurement range (30 pmol/l), the Phoenix kit had incomplete recovery in plasma and the Bio-Rad kit was insensitive (detection limit in plasma 40 pmol/l). The pattern of postprandial GLP-1 responses in clinical samples was similar between the kits tested, but the absolute concentrations measured varied.CONCLUSIONS: The specificity and sensitivity of commercially available kits for analysis of GLP-1 levels varies considerably. This should be taken into account when selecting which assay to use and when comparing data from different studies.",
author = "Bak, {Monika Judyta} and Albrechtsen, {Nicolai Jacob Wewer} and Jens Pedersen and Knop, {Filip Krag} and {Vilsb{\o}ll Lauritsen}, Tina and J{\o}rgensen, {Nils B} and Bolette Hartmann and Deacon, {Carolyn F.} and Dragsted, {Lars Ove} and Holst, {Jens Juul}",
note = "CURIS 2014 NEXS 349",
year = "2014",
doi = "10.1111/dom.12352",
language = "English",
volume = "16",
pages = "1155--1164",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "11",

}

RIS

TY - JOUR

T1 - Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1)

T2 - Implications for GLP-1 measurements in clinical studies

AU - Bak, Monika Judyta

AU - Albrechtsen, Nicolai Jacob Wewer

AU - Pedersen, Jens

AU - Knop, Filip Krag

AU - Vilsbøll Lauritsen, Tina

AU - Jørgensen, Nils B

AU - Hartmann, Bolette

AU - Deacon, Carolyn F.

AU - Dragsted, Lars Ove

AU - Holst, Jens Juul

N1 - CURIS 2014 NEXS 349

PY - 2014

Y1 - 2014

N2 - AIMS: To evaluate performances of commercially available glucagon-like peptide-1 (GLP-1) assays and implications for clinical studies.MATERIALS AND METHODS: Known concentrations (5-300 pmol/l) of synthetic GLP-1 isoforms (GLP-1 1-36NH2 , 7-36NH2 , 9-36NH2 , 1-37, 7-37 and 9-37) were added to the matrix (assay buffer) supplied with ten different kits and to human plasma, and recoveries determined. Assays giving meaningful results were analysed for precision and sensitivity by repeated analysis and ability to discriminate low concentrations. Endogenous GLP-1 levels in clinical samples were assessed with 3 commercial kits.RESULTS: The USCN LIFE assay detected none of the GLP-1 isoforms. The active GLP-1 ELISAs from Millipore and DRG seemed identical and were specific for intact GLP-1 in buffer and plasma. The Meso Scale Discovery Total GLP-1 kit detected all six GLP-1 isoforms, although recovery of non-active forms was incomplete, especially in plasma. Millipore Total GLP-1 ELISA kit detected all isoforms in buffer, but mainly amidated forms in plasma. The Alpco, Phoenix and Bio-Rad kits detected only amidated GLP-1,but the Alpco kit had a limited measurement range (30 pmol/l), the Phoenix kit had incomplete recovery in plasma and the Bio-Rad kit was insensitive (detection limit in plasma 40 pmol/l). The pattern of postprandial GLP-1 responses in clinical samples was similar between the kits tested, but the absolute concentrations measured varied.CONCLUSIONS: The specificity and sensitivity of commercially available kits for analysis of GLP-1 levels varies considerably. This should be taken into account when selecting which assay to use and when comparing data from different studies.

AB - AIMS: To evaluate performances of commercially available glucagon-like peptide-1 (GLP-1) assays and implications for clinical studies.MATERIALS AND METHODS: Known concentrations (5-300 pmol/l) of synthetic GLP-1 isoforms (GLP-1 1-36NH2 , 7-36NH2 , 9-36NH2 , 1-37, 7-37 and 9-37) were added to the matrix (assay buffer) supplied with ten different kits and to human plasma, and recoveries determined. Assays giving meaningful results were analysed for precision and sensitivity by repeated analysis and ability to discriminate low concentrations. Endogenous GLP-1 levels in clinical samples were assessed with 3 commercial kits.RESULTS: The USCN LIFE assay detected none of the GLP-1 isoforms. The active GLP-1 ELISAs from Millipore and DRG seemed identical and were specific for intact GLP-1 in buffer and plasma. The Meso Scale Discovery Total GLP-1 kit detected all six GLP-1 isoforms, although recovery of non-active forms was incomplete, especially in plasma. Millipore Total GLP-1 ELISA kit detected all isoforms in buffer, but mainly amidated forms in plasma. The Alpco, Phoenix and Bio-Rad kits detected only amidated GLP-1,but the Alpco kit had a limited measurement range (30 pmol/l), the Phoenix kit had incomplete recovery in plasma and the Bio-Rad kit was insensitive (detection limit in plasma 40 pmol/l). The pattern of postprandial GLP-1 responses in clinical samples was similar between the kits tested, but the absolute concentrations measured varied.CONCLUSIONS: The specificity and sensitivity of commercially available kits for analysis of GLP-1 levels varies considerably. This should be taken into account when selecting which assay to use and when comparing data from different studies.

U2 - 10.1111/dom.12352

DO - 10.1111/dom.12352

M3 - Journal article

C2 - 25041349

VL - 16

SP - 1155

EP - 1164

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 11

ER -

ID: 119240374